KDR and hypertensive disorder: Hypertension, proteinuria, and hand-foot syndrome are known adverse events associated with VEGF/VEGFR inhibition, frequently reported in studies of angiogenesis inhibitors such as bevacizumab [11], ramucirumab [12, 13], sorafenib [13], lenvatinib [14], and apatinib [6].